Formulary guidance and transparency from P&T to point of care

Trends that Matter for 2015 Approvals

Posted by Matt Breese on Jan 4, 2016

Find me on:

A review of 2015 reveals some key trends in drug pharmaceutical manufacturer activity and provides some insights for the 2016 outlook. The following post organizes a few of those trends with links to healthcare influencers across the industry:

1. An FDA activity analysis from BioMedTracker via Forbes shows the increased percentage of new molecular entity approvals for 2015




2. CenterWatch lists out the products approved by the FDA in 2015. These approvals significantly affect the landscapes of several classes, including PCSK9s, antipsychotics and cystic fibrosis treatments.

See the Full List on CenterWatch


3. The FDA Law Blog reveals the dramatic increase in first action approval rates during the past 20 years. 2015 marks the highest percentage in history.


Read More via


4. The amount of application withdrawals hit a potential low in recent years, according to a review by the FDA Law Blog that specifically focused on safety and efficacy. 


Read the Full Piece Here


Follow us on Twitter to stay current with new drug approvals and how they affect the healthcare network from P&T to point of care.

Follow MMIT on Twitter

Topics: Industry Trends, Market Access